FDA warns CellGenuity over unapproved amniotic/umbilical products and serious sterility failures.
What happened
FDA inspected the Grapevine, TX facility from October 26 to November 10, 2021, and reviewed the company's website. It found allogeneic umbilical cord- and amniotic-derived products intended for injection and purported to be sterile, marketed to treat diseases, without an approved biologics license or an IND. FDA also documented significant deviations from current good manufacturing practice (CGMP), including unvalidated aseptic processing, inadequate cleaning and gowning, sterility and endotoxin failures, and missing investigations.
What FDA found
Marketed biological products without an approved biologics license application (BLA) or an investigational new drug (IND) application.
42 U.S.C. 262(a); 21 U.S.C. 355(i); 21 CFR Part 312Failed to validate aseptic processing, establish environmental monitoring, use adequate gowning, and establish filter sterilization procedures.
21 CFR 211.113(b)Failed to validate cleaning and disinfection and lacked adequate procedures, while environmental samples routinely detected spore-forming microorganisms.
21 CFR 211.42(c)(10)(v)Failed to validate manufacturing processes and had no written manufacturing procedures before June 2021.
21 CFR 211.100(a)Failed to investigate sterility and endotoxin failures and environmental monitoring failures to find root cause or product impact.
21 CFR 211.192Assigned expiration dates without stability testing.
21 CFR 211.166(a)
What FDA wants
FDA asks for a written response within 15 working days describing specific corrective actions and documentation, including the disposition of remaining inventory and the impact on distributed products.
Who should pay attention
- clinics and healthcare providers who inject amniotic or umbilical cord products
- distributors or brands sourcing CellGenuity products
- HCT/P and biologic manufacturers relying on section 361 regulation
This is a summary. Read the original letter on fda.gov.